Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells

Biochemical Pharmacology

Volumn 51, Issue 10, 1996, Pages 1341-1348

  Praet, Michel ^a   Stryckmans, Pierre ^b   Ruysschaert, Jean Marie ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

anthracyclines; flow cytometry; K562 cells; multidrug resistance; P glycoprotein; transport kinetics

Indexed keywords

4' IODOESORUBICIN; ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ESORUBICIN; GLYCOPROTEIN P; IDARUBICIN; MEMBRANE PROTEIN; NEMORUBICIN;

ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; DRUG TRANSPORT; DRUG UPTAKE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; KINETICS; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0029943722     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00042-1     Document Type: Article

References (28)

1. Pastan I and Gottesman MM, Multiple-drug resistance in human cancers. N Engl J Med 316: 1388-1393, 1987.
2. Bradley G, Juranka PF and Ling V, Mechanisms of multidrug resistance. Biochim Biophys Acta 948: 87-128, 1988.
3. Chin K-V, Pastan I and Gottesman MM, Function and regulation of the human multidrug resistance gene. Adv Cancer Res 60: 157-180, 1993.
4. Higgins CF, ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8: 67-113, 1992.
5. Higgins CF, The ABC of channel regulation. Cell 82: 693-696, 1995.
6. Gottesman MM and Pastan I, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
7. Scarborough GA, Drug-stimulated ATPase activity of the human P-glycoprotein. J Bioenerg Biomembr 27: 37-41, 1995.
8. Dalton WS, Drug resistance: modulation in the laboratory and the clinic. Semin Oncol 20: 64-69, 1993.
9. Yusa K and Tsuruo T, Reversal mechanism of multidrug-resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 49: 5002-5006, 1989.
10. Merlin JL, Guerci A, Marchai S, Missoum N, Ramacci C, Humbert J-C, Tsuruo T and Guerci O, Comparative evaluation of S9788, verapamil and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. Blood 84: 262-269, 1994.
11. Sonneveld P, Durie BG, Lokhurst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Lowenberg G and Nooter K, Modulation of multi-drug resistant multiple myeloma by cyclosporin. Lancet 340: 255-259, 1992.
12. Sikic BI, Modulation of multidrug resistance: at the threshold. J Clin Oncol 11: 1629-1635, 1993.
13. Kaye SB, P-glycoprotein (P-gp) and drug resistance - time for reappraisal? Br J Cancer 67: 641-643, 1993.
14. Ripamonti M, Pezzoni G, Pesenti E, Pastori A, Farao M, Bargiotti A, Suarato A, Spreafico F and Grandi M, In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells. Br J Cancer 65: 703-707, 1992.
15. Coley HM, Twentyman PR and Workman P, Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines and further resistance modification by verapamil and cyclosporin A. Cancer Chemother Pharmacol 24: 284-290, 1989.
16. Coley HM, Twentyman PR and Workman P, Improved cellular accumulation is characteristic of anthracycline which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol 38: 4467-4475, 1989.
17. Tarasiuk J, Frézard F, Garnier-Suillerot A and Gattegno L, Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration. Biochim Biophys Acta 1013: 109-117, 1989.
18. Frézard F and Garnier-Suillerot A, Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells. Eur J Biochem 196: 483-491, 1991.
19. Jardillier JC, Colin M, Bobichon H, Akeli MG, Delvincourt C and Madoulet C, Le phénotype de résistance multidrogue: quelques caractéristiques morphologiques et biologiques autres que la pompe à efflux. Bull Cancer 81: 392-399, 1994.
20. Léonce S and Burbridge M, Flow cytometry: a useful technique in the study of multidrug resistance. Biol Cell 78: 63-68, 1993.
21. Loos M, Debusscher M, Massy M, Dorval C, Delforge A, Bron D, Bernier M and Stryckmans P, Evaluation of the MDR phenotype of acute non lymphoblastic leukemia. In: Drug Resistance in Leukemia and Lymphoma - the Clinical Value of Laboratory Studies (Eds. Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM and Veerman AJP), pp. 55-58. Harwood Academic Publishers, Chuv, Switzerland, 1993.
22. Egorin MJ, Clawson RE, Ross LA and Bachur NR, Cytofluorescence localization of adriamycin and daunorubicin. Cancer Res 34: 2243-2245, 1974.
23. Durand RE and Olive PL, Flow cytometry studies of intracellular adriamycin in single cells in vitro. Cancer Res 41: 3489-3494, 1981.
24. Pereira E and Garnier-Suillerot A, Correlation between the short-term measurements of drug accumulation in living cells and the long-term growth inhibition. Biochem Pharmacol 47: 1851-1857, 1994.
25. Berman E and McBride M, Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79: 3267-3273, 1992.
26. Pereira E, Borrel MN, Fiallo M and Garnier-Suillerot A, Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells. Biochim Biophys Acta 1225: 209-216, 1994.
27. Friche E, Jensen B, Skovsgaard T and Nissen NI, Evaluation of 4′-deoxy-4′-iododoxorubicin in sensitive and resistant Ehrlich ascites tumour. J Cell Pharmacol 1: 57-65, 1990.
28. Coley HM, Twentyman PR and Workman P, The efflux of anthracyclines in multidrug-resistant cell lines. Biochem Pharmacol 46: 1317-1326, 1993.